A Phase I Dose Escalation And Expanded Cohort Study Of Pf-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (Sclc), Castration Resistant Prostate Cancer (Crpc) And Follicular Lymphoma (fl)
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Apr 2018
At a glance
- Drugs PF-06821497 (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Prostate cancer; Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 13 Apr 2018 Planned End Date changed from 1 Oct 2020 to 1 Sep 2020.
- 13 Apr 2018 Planned primary completion date changed from 1 Oct 2020 to 1 Sep 2020.
- 09 Apr 2018 Planned End Date changed from 1 Jul 2021 to 1 Oct 2020.